Tags

Type your tag names separated by a space and hit enter

Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.
Aliment Pharmacol Ther. 2007 Aug 01; 26(3):475-86.AP

Abstract

BACKGROUND

Health-related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS).

AIM

To study the effects of fermented milk containing Bifidobacterium animalis DN-173 010 and yoghurt strains on the IBS in a multicentre, double-blind, controlled trial.

METHODS

A total of 274 primary care adults with constipation-predominant IBS (Rome II) were randomized to consume for 6 weeks either the test fermented milk or a heat-treated yoghurt (control). HRQoL and digestive symptoms were assessed after 3 and 6 weeks on an intention-to-treat population of 267 subjects.

RESULTS

The HRQoL discomfort score, the primary endpoint, improved (P < 0.001) in both groups at weeks 3 and 6. The responder rate for the HRQoL discomfort score was higher (65.2 vs. 47.7%, P < 0.005), as was the decrease in bloating score [0.56 +/- (s.d.)1.01 vs. 0.31 +/- 0.87, P = 0.03], at week 3 in the test vs. the control group. In those subjects with <3 stools/week, stool frequency increased (P < 0.001) over 6 weeks in the test vs. control group.

CONCLUSIONS

This study suggests a beneficial effect of a probiotic food on discomfort HRQoL score and bloating in constipation-predominant IBS, and on stool frequency in subjects with <3 stools/week.

Links

Aggregator Full Text

Authors+Show Affiliations

Guyonnet D
Danone Research, Route Départementale 128, 91767 Palaiseau, France. denis.guyonnet@danone.com
Chassany O
No affiliation info available
Ducrotte P
No affiliation info available
Picard C
No affiliation info available
Mouret M
No affiliation info available
Mercier CH
No affiliation info available
Matuchansky C
No affiliation info available

MeSH

AdolescentAdultAgedBifidobacteriales InfectionsBifidobacteriumDouble-Blind MethodFemaleHumansIrritable Bowel SyndromeMaleMiddle AgedPrimary Health CareProbioticsQuality of LifeTreatment OutcomeYogurt

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17635382

Citation

Guyonnet, D, et al. "Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 On the Health-related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: a Multicentre, Randomized, Double-blind, Controlled Trial." Alimentary Pharmacology & Therapeutics, vol. 26, no. 3, 2007, pp. 475-86.
Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26(3):475-86.
Guyonnet, D., Chassany, O., Ducrotte, P., Picard, C., Mouret, M., Mercier, C. H., & Matuchansky, C. (2007). Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 26(3), 475-86.
Guyonnet D, et al. Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 On the Health-related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: a Multicentre, Randomized, Double-blind, Controlled Trial. Aliment Pharmacol Ther. 2007 Aug 1;26(3):475-86. PubMed PMID: 17635382.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. AU - Guyonnet,D, AU - Chassany,O, AU - Ducrotte,P, AU - Picard,C, AU - Mouret,M, AU - Mercier,C-H, AU - Matuchansky,C, PY - 2007/7/20/pubmed PY - 2007/12/15/medline PY - 2007/7/20/entrez SP - 475 EP - 86 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 26 IS - 3 N2 - BACKGROUND: Health-related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS). AIM: To study the effects of fermented milk containing Bifidobacterium animalis DN-173 010 and yoghurt strains on the IBS in a multicentre, double-blind, controlled trial. METHODS: A total of 274 primary care adults with constipation-predominant IBS (Rome II) were randomized to consume for 6 weeks either the test fermented milk or a heat-treated yoghurt (control). HRQoL and digestive symptoms were assessed after 3 and 6 weeks on an intention-to-treat population of 267 subjects. RESULTS: The HRQoL discomfort score, the primary endpoint, improved (P < 0.001) in both groups at weeks 3 and 6. The responder rate for the HRQoL discomfort score was higher (65.2 vs. 47.7%, P < 0.005), as was the decrease in bloating score [0.56 +/- (s.d.)1.01 vs. 0.31 +/- 0.87, P = 0.03], at week 3 in the test vs. the control group. In those subjects with <3 stools/week, stool frequency increased (P < 0.001) over 6 weeks in the test vs. control group. CONCLUSIONS: This study suggests a beneficial effect of a probiotic food on discomfort HRQoL score and bloating in constipation-predominant IBS, and on stool frequency in subjects with <3 stools/week. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/17635382/full_citation L2 - https://doi.org/10.1111/j.1365-2036.2007.03362.x DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓110]

Related Citations

    More

    Others Viewed